Anthracycline News and Research

RSS
Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.
FDA approves Halaven therapy for metastatic late-stage breast cancer

FDA approves Halaven therapy for metastatic late-stage breast cancer

Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer

Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer

Cell Therapeutics announces submission of MAA to European Medicines Agency for Pixuvri

Cell Therapeutics announces submission of MAA to European Medicines Agency for Pixuvri

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

EMA Pediatric Committee adopts positive opinion for CTI's Pixuvri for lymphoid malignancies, solid tumors

EMA Pediatric Committee adopts positive opinion for CTI's Pixuvri for lymphoid malignancies, solid tumors

Celgene acquires Abraxis BioScience

Celgene acquires Abraxis BioScience

Impact of cancer treatment on cardiovascular function

Impact of cancer treatment on cardiovascular function

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL

Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

CTI announces EMEA's validation of expanded PIP for pixantrone

CTI announces EMEA's validation of expanded PIP for pixantrone

CTI files SPA with FDA for new pixantrone phase III trial in relapsed or refractory aggressive B-Cell NHL

CTI files SPA with FDA for new pixantrone phase III trial in relapsed or refractory aggressive B-Cell NHL

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Genentech disappointed with FDA ODAC's recommendation against Avastin

Genentech disappointed with FDA ODAC's recommendation against Avastin

CTI signs agreement with NerPharMa for long-term manufacture of pixantrone

CTI signs agreement with NerPharMa for long-term manufacture of pixantrone

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML